AssetMark Inc
MYGN icon

AssetMark Inc’s Myriad Genetics MYGN Stock Holding History

AssetMark Inc’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51
Closed -$314 – 3542
2025
Q4 		$314 Buy
+51
New +$370 ﹤0.01% 3184
2023
Q4 		– Sell
-182
Closed -$2.92K – 1961
2023
Q3 		$2.92K Buy
182
+51
+39% +$970 ﹤0.01% 1438
2023
Q2 		$3.04K Hold
131
– – ﹤0.01% 1386
2023
Q1 		$3.04K Sell
131
-86
-40% -$1.75K ﹤0.01% 1365
2022
Q4 		$3.15K Buy
217
+1
+0.5% +$19 ﹤0.01% 1398
2022
Q3 		$4K Hold
216
– – ﹤0.01% 1331
2022
Q2 		$4K Buy
216
+123
+132% +$2.55K ﹤0.01% 1322
2022
Q1 		$2K Sell
93
-4
-4% -$102 ﹤0.01% 1426
2021
Q4 		$3K Buy
97
+7
+8% +$203 ﹤0.01% 1325
2021
Q3 		$3K Hold
90
– – ﹤0.01% 1225
2021
Q2 		$3K Sell
90
-5
-5% -$144 ﹤0.01% 1164
2021
Q1 		$3K Sell
95
-14
-13% -$397 ﹤0.01% 1115
2020
Q4 		$2K Hold
109
– – ﹤0.01% 1222
2020
Q3 		$1K Hold
109
– – ﹤0.01% 1253
2020
Q2 		$1K Buy
109
+38
+54% +$540 ﹤0.01% 1191
2020
Q1 		$1K Buy
71
+10
+16% +$211 ﹤0.01% 1274
2019
Q4 		$2K Buy
61
+9
+17% +$248 ﹤0.01% 1248
2019
Q3 		$1K Sell
52
-52
-50% -$1.51K ﹤0.01% 1247
2019
Q2 		$3K Buy
104
+29
+39% +$819 ﹤0.01% 1122
2019
Q1 		$2K Sell
75
-8
-10% -$244 ﹤0.01% 1178
2018
Q4 		$2K Sell
83
-49
-37% -$1.76K ﹤0.01% 1223
2018
Q3 		$6K Sell
132
-16
-11% -$711 ﹤0.01% 1140
2018
Q2 		$6K Sell
148
-2
-1% -$68 ﹤0.01% 1140
2018
Q1 		$4K Sell
150
-5
-3% -$169 ﹤0.01% 1187
2017
Q4 		$5K Buy
+155
New +$5.23K ﹤0.01% 1252

Other funds holding MYGN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AssetMark Inc's MYGN Position: Q1 2026 in Review

AssetMark Inc sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 51 shares — an estimated $314 sold.

AssetMark Inc first reported a position in MYGN in Q4 2017 and held it in 25 quarters. The position peaked at $6K in Q3 2018. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • AssetMark Inc reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • AssetMark Inc sold 51 Myriad Genetics shares in Q1 2026, an estimated $314.
  • AssetMark Inc first reported a position in Myriad Genetics in Q4 2017 and held it in 25 quarters.
  • AssetMark Inc's Myriad Genetics position peaked at $6K in Q3 2018.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.